Only 33% of Big Employers Now Cover GLP-1s
Only 33% of Big Employers Now Cover GLP-1s
Only 33% of Big Employers Now Cover GLP-1s
Key points
اہم نکات
मुख्य बातें
- More American employers are dropping coverage for weight-loss drugs such as Wegovy and Zepbound, USA Today reports.
- Starbucks recently halted coverage for the drugs when prescribed for obesity, and a KFF survey found only 33 percent of large employers now cover GLP-1s for obesity, down from 43 percent a year ago.
- Workers who lose coverage can buy directly from the drugmakers, with the lowest-dose Wegovy pill at 149 dollars a month and Zepbound injections from 299 dollars, or turn to third-party weight-loss vendors.
- More American employers are dropping coverage for weight-loss drugs such as Wegovy and Zepbound, USA Today reports.
- Starbucks recently halted coverage for the drugs when prescribed for obesity, and a KFF survey found only 33 percent of large employers now cover GLP-1s for obesity, down from 43 percent a year ago.
- Workers who lose coverage can buy directly from the drugmakers, with the lowest-dose Wegovy pill at 149 dollars a month and Zepbound injections from 299 dollars, or turn to third-party weight-loss vendors.
- More American employers are dropping coverage for weight-loss drugs such as Wegovy and Zepbound, USA Today reports.
- Starbucks recently halted coverage for the drugs when prescribed for obesity, and a KFF survey found only 33 percent of large employers now cover GLP-1s for obesity, down from 43 percent a year ago.
- Workers who lose coverage can buy directly from the drugmakers, with the lowest-dose Wegovy pill at 149 dollars a month and Zepbound injections from 299 dollars, or turn to third-party weight-loss vendors.
More American employers are dropping coverage for weight-loss drugs such as Wegovy and Zepbound, USA Today reports. Starbucks recently halted coverage for the drugs when prescribed for obesity, and a KFF survey found only 33 percent of large employers now cover GLP-1s for obesity, down from 43 percent a year ago. Workers who lose coverage can buy directly from the drugmakers, with the lowest-dose Wegovy pill at 149 dollars a month and Zepbound injections from 299 dollars, or turn to third-party weight-loss vendors.
More American employers are dropping coverage for weight-loss drugs such as Wegovy and Zepbound, USA Today reports. Starbucks recently halted coverage for the drugs when prescribed for obesity, and a KFF survey found only 33 percent of large employers now cover GLP-1s for obesity, down from 43 percent a year ago. Workers who lose coverage can buy directly from the drugmakers, with the lowest-dose Wegovy pill at 149 dollars a month and Zepbound injections from 299 dollars, or turn to third-party weight-loss vendors.
More American employers are dropping coverage for weight-loss drugs such as Wegovy and Zepbound, USA Today reports. Starbucks recently halted coverage for the drugs when prescribed for obesity, and a KFF survey found only 33 percent of large employers now cover GLP-1s for obesity, down from 43 percent a year ago. Workers who lose coverage can buy directly from the drugmakers, with the lowest-dose Wegovy pill at 149 dollars a month and Zepbound injections from 299 dollars, or turn to third-party weight-loss vendors.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।